Learn about the proven efficacy of AZEDRA with actual patient cases from the pivotal Phase II trial
Patient background and medical history
Relevant medical history
Date of diagnosis:July 2006
Antihypertensive medication:Doxazosin 1 mg qd
Prior surgeries:Right adrenalectomy in July 2006
Prior systemic therapies:None
Tumor Profile
Tumor type:Pheochromocytoma
Secretory profile: Norepinephrine, epinephrine
Metastatic locations:Lung, small bowel
MIBG avidity:Confirmed through patient workup and dosimetric scan
Baseline labs
Test
Normal Range
Patient Value
Creatinine Clearance
90–140 mL/min
NR
Bilirubin
5.13–17.1 µmol/L
6.84 µmol/L
Hemoglobin
120–160 g/L
115 g/L
Leukocytes
4–11 x109/L
6.3 x109/L
Neytrophils
2–8.25 x109/L
3.92 x109/L
Platelets
150–450 x109/L
311 x109/L
Posterior I-131 MIBG
Scan following a therapeutic dose of AZEDRA (435 mCi). Numerous metastatic lesions in the lung and small bowel are best appreciated on this posterior scan and are indicated by arrows.
Results following treatment with AZEDRA
AZEDRA therapeutic dosing
First dose administered in March 2010, second dose 3 months later in June 2010
Patient name and photo are for illustrative purposes but clinical details are derived from an individual treated in the Phase II trial of AZEDRA. Individual results may vary in clinical use of AZEDRA in patient with pheochromocytoma and paraganglioma (PPGL).
Scan following the first therapeutic dose of AZEDRA (487 mCi) showed increased activity in the left lower lobe lung nodule (long arrow) and slightly increased activity in both adrenal glands (short arrows) which may be physiologic. The abdominal masses noted on the CT are not appreciated on this exam.
Results following treatment with AZEDRA
AZEDRA therapeutic dosing
First dose administered in March 2010, second dose 3 months later in June 2010
Patient name and photo are for illustrative purposes but clinical details are derived from an individual treated in the Phase II trial of AZEDRA. Individual results may vary in clinical use of AZEDRA in patient with pheochromocytoma and paraganglioma (PPGL).